1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.Read more
Cybin is betting that psychedelic treatments can fit smoothly into everyday mental health clinics, making it easier for more patients to get care without overwhelming staff. The big upside comes if its late-stage trials succeed and clinic and insurance partners embrace this model, but delays, spending needs, or slow adoption could hold it back.Read more
Cybin is trying to bring psychedelic-style treatments for depression and anxiety into clinics in a way that fits today’s mental-health workflows, which could speed up real-world use if the late-stage trials deliver. The big question is whether the studies succeed and whether insurers and clinics adopt the model fast enough to turn scientific progress into a sustainable business.Read more
Cybin is racing to bring psychedelic-based treatments for depression and anxiety through late-stage trials, but it may need to raise more money before it ever sells a product. If the studies run smoothly and clinics and insurers embrace short, streamlined treatment sessions, the payoff could be meaningful—but a delay, weaker results, or slow adoption could quickly change the story.Read more
No trending discussion available.
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
